Emalex Biosciences Announces Completion of Patient Enrollment in Phase 2b Clinical Trial Evaluating Ecopipam (EBS-101) for Pediatric Patients with Tourette Syndrome

CHICAGO, June 22, 2021 /PRNewswire/ -- Emalex Biosciences, Inc. ( " Emalex " ), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders,...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials